Laurie Andrews, RN, MPH
Program Manager, Yale Antivirals and Vaccine Research ProgramDownloadHi-Res Photo
Cards
Contact Info
About
Titles
Program Manager, Yale Antivirals and Vaccine Research Program
Appointments
Departments & Organizations
Education & Training
- MPH
- University of Connecticut, Public Health (1999)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Laurie Andrews's published research.
Publications Timeline
A big-picture view of Laurie Andrews's research output by year.
Gerald Friedland, MD
Frederick Lewis Altice, MD, MA
Sheela Shenoi, MD, MPH, FIDSA
Heidi J Zapata, MD, PhD
Lydia Aoun-Barakat, MD
Onyema Ogbuagu, MBBCh, FACP, FIDSA
20Publications
371Citations
Publications
2023
Community health workers can be trained to identify patients eligible for tuberculosis preventive therapy, but encounter barriers to programme implementation in KwaZulu-Natal, South Africa
Norton S, Moll A, Madi J, Nkomo N, Brooks R, Andrews L, Shenoi S. Community health workers can be trained to identify patients eligible for tuberculosis preventive therapy, but encounter barriers to programme implementation in KwaZulu-Natal, South Africa. African Journal Of AIDS Research 2023, 22: 131-135. PMID: 37337826, DOI: 10.2989/16085906.2023.2213213.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTuberculosis preventive therapyCommunity health workersLargest HIV epidemicCause of deathNon-communicable diseasesHealth workersPreventive therapyRural resource-limited settingsHigh TB incidence ratesFurther implementation researchTB incidence rateRate of referralResource-limited settingsMedian ageTreatment initiationHIV epidemicIncidence rateRural South AfricaHIVInfectious diseasesTuberculosisImplementation researchScreening resultsDiseasePatientsPerceived stigma related to TB preventive therapy
Palacios C, Hough M, Shrestha R, Moll A, Kompala T, Andrews L, Shenoi S. Perceived stigma related to TB preventive therapy. The International Journal Of Tuberculosis And Lung Disease 2023, 27: 209-214. PMID: 36855038, DOI: 10.5588/ijtld.22.0570.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTB preventative therapyTB preventive therapyAnonymous cross-sectional surveyBurden of TBCommunity-dwelling adultsRural South African communityCross-sectional surveyPreventive therapyMean agePreventative therapyEndemic settingsPatient's familyKruskal-Wallis testStigma scoresRural South AfricaPoisson regressionNovel interventionsSouth African communityTherapyLess stigmaDescriptive statisticsFamily membersStigmaTBTwo-factor solution
2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4
2021
Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV
Tuan JJ, Zapata H, Critch‐Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 vaccineCOVID-19 vaccinationFirst doseSeroconversion ratesSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionYale New Haven Health SystemPrior COVID-19 infectionSyndrome coronavirus 2 infectionSafe COVID-19 vaccineIntegrase strand transfer inhibitorsAnti-spike IgGPositive IgG responseTwo-dose seriesCoronavirus 2 infectionVaccine-induced immunityDurability of protectionCOVID-19 infectionStrand transfer inhibitorsAntiretroviral regimenBNT162b2 vaccineNew seroconversionsPositive IgGQualitative antibodyStructural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa
Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Global Public Health 2021, 17: 555-568. PMID: 33650939, PMCID: PMC8410883, DOI: 10.1080/17441692.2021.1892793.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTuberculosis preventive treatmentPrimary healthcare clinicsTPT initiationWorld Health OrganizationAntiretroviral therapyPreventive treatmentRural South AfricaHIV/TB servicesBurden of HIVOnly independent correlatePrimary care clinicsClinic-level factorsPatient-level characteristicsPrimary care providersHealth Services frameworkEvidence-based strategiesQuality improvement strategiesTB servicesClinical factorsCare clinicsIndependent correlatesMedical recordsPromoting ActionCare providersHealthcare clinics
2019
1883. Factors Associated with Stigma Toward Isoniazid-Preventative Therapy in a Rural Community of South Africa
Palacios C, Kompala T, Moll A, Andrews L, Shenoi S. 1883. Factors Associated with Stigma Toward Isoniazid-Preventative Therapy in a Rural Community of South Africa. Open Forum Infectious Diseases 2019, 6: s51-s52. PMCID: PMC6808667, DOI: 10.1093/ofid/ofz359.113.Peer-Reviewed Original ResearchConceptsIsoniazid preventative therapyTB knowledgePresence of stigmaMarital statusPrevention of tuberculosisMultivariable linear regressionRural KwaZulu-Natal ProvinceChi-square testIPT implementationTB screeningTB transmissionHigher knowledge levelMean ageTB scoreHIV stigmaKruskal-Wallis testKnowledge scoreTuberculosisPoor knowledgeLinear regressionHIVMean scoreTotal knowledgeTherapyTreatment
2017
Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts
Shenoi SV, Moll AP, Brooks RP, Kyriakides T, Andrews L, Kompala T, Upadhya D, Altice FL, Eksteen FJ, Friedland G. Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases 2017, 4: ofx092. PMID: 28695145, PMCID: PMC5499582, DOI: 10.1093/ofid/ofx092.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHuman immunodeficiency virusIntensive case findingCase findingResistant TBTB casesHIV testingRural South AfricaOverall case notification rateConcurrent HIV testingHIV coinfection rateHIV-negative tuberculosisMedian CD4 countCD4 cell countHIV/TBDrug-resistant TBCase notification ratesCase-finding strategyHIV-positive individualsHigh-risk populationTB symptom screeningPopulation-level ratesCD4 countTuberculosis symptomsSymptom screeningTB elimination
2015
A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study)
Frank C, Kyriakides T, Omar A, Friedland G, Andrews L, Melbourne K, Kozal M. A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study). Open Forum Infectious Diseases 2015, 2: 1082. DOI: 10.1093/ofid/ofv133.795.Peer-Reviewed Original Research
2013
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2011
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal Of Drug And Alcohol Abuse 2011, 37: 224-228. PMID: 21438849, DOI: 10.3109/00952990.2011.568081.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTPV/rSteady-state pharmacokinetic evaluationGlucuronide metabolitesBUP/naloxoneHIV-negative subjectsHIV-seronegative subjectsBuprenorphine/naloxoneSteady-state pharmacokineticsCytochrome P450 3A4Ritonavir effectsPharmacodynamic consequencesPharmacokinetic evaluationBuprenorphineNorBUPCombined inhibitionNaloxoneCurve AUCP450 3A4AUCSignificant increasePharmacokineticsTipranavirPrevious reportsSubjectsMetabolites